Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P15248
UPID:
IL9_HUMAN
Alternative names:
Cytokine P40; T-cell growth factor P40
Alternative UPACC:
P15248
Background:
Interleukin-9, known as Cytokine P40 or T-cell growth factor P40, is a multifunctional cytokine secreted by T-helper 2 lymphocytes, mast cells, and NKT cells. It plays pivotal roles in immune responses against parasites, influencing intestinal epithelial permeability and adaptive immunity. It promotes the differentiation of specific T-cell subsets, including TH17, and the proliferation and differentiation of mast cells. Its action is mediated through the IL9R and IL2RG receptor units, activating JAK1 and JAK3 kinases, leading to STAT1, STAT3, and STAT5-mediated transcriptional programs.
Therapeutic significance:
Understanding the role of Interleukin-9 could open doors to potential therapeutic strategies, particularly in enhancing immune responses against parasitic infections and modulating immune cell differentiation.